Coty Inc. is a global beauty company that specializes in the development, manufacturing, and marketing of a wide range of beauty products, including perfumes, cosmetics, and skincare solutions. With a diverse portfolio that includes both established and emerging brands, Coty aims to enhance the beauty experience for consumers through innovative and high-quality offerings. The company focuses on creating iconic fragrances, cutting-edge makeup products, and luxurious skincare treatments, catering to a variety of customer preferences and market segments. Through its commitment to sustainability and social responsibility, Coty continues to evolve its product lines and business practices to meet the changing needs of consumers around the world. Read More
The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Inter Parfums (NASDAQ:IPAR) and the best and worst performers in the personal care industry.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at personal care stocks, starting with Medifast (NYSE:MED).
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Estée Lauder (NYSE:EL) and its peers.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Shareholders of Coty would probably like to forget the past six months even happened. The stock has dropped 42.5% and now trades at a new 52-week low of $5.40. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at personal care stocks, starting with USANA (NYSE:USNA).
Let’s dig into the relative performance of The Honest Company (NASDAQ:HNST) and its peers as we unravel the now-completed Q4 personal care earnings season.
Coty Inc. (Coty Inc. (NYSE: COTY) (Paris: COTY) ("Coty" or "the Company") today announced the conclusion of its partnership with Kim Kardashian and the SKKN by Kim (“SKKN”) brand, with the closing of the sale of its 20% stake in the brand to SKIMS. Following the transaction, SKIMS will be uniting the beauty and lifestyle ventures under one brand.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the personal care industry, including e.l.f. Beauty (NYSE:ELF) and its peers.
Coty (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies, with an iconic portfolio of brands across fragrance, color cosmetics, skin and body care, hosted a cross-industry roundtable to discuss restrictive beauty ideals and definitions. As the next chapter of the award-winning #UndefineBeauty campaign, the panel debunks beauty myths and includes perspectives on neuroscience, art, social media, sociology, and mental health, and underscores the need for collective action to drive change.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the personal care industry, including BeautyHealth (NASDAQ:SKIN) and its peers.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Coty (NYSE:COTY) and its peers.
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums).
That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Stifel analyst Mark S. Astrachan lowered Coty's price target from $8.5 to $8, maintaining a Hold rating. Despite adjusted EBITDA growth, Coty's second-quarter FY25 results revealed a 1% YoY decline in net revenue and a challenging outlook for the second half of FY25.
